OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
30092755

Nantong JiangTian Chemical Co Ltd

Specialty ChemicalsVerified

Nantong JiangTian Chemical Co Ltd has a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.72, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -108.6 million CNY, driven by capital expenditures of -166.3 million CNY, which may signal ongoing investment in operations. Profitability metrics show a return on equity of 2.01% and a return on assets of 0.93%, both below the typical thresholds for healthy performance in the specialty chemicals industry. The company's operating income of 22.6 million CNY and net income of 19.5 million CNY suggest limited profitability relative to its asset base. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes. The company's total revenue of 1.55 billion CNY is derived from a single disclosed segment, with no further breakdown provided. Growth trajectory is constrained by the company's current financial position. The company's free cash flow is negative, and capital expenditures are high, which may limit reinvestment in growth opportunities. There is no disclosed revenue growth in the most recent period, and no forward-looking guidance is available to assess future performance. The company faces moderate liquidity risk due to its negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no recent or disclosed share issuance activity. The company's capital structure remains stable, with no signs of imminent equity dilution. No recent filings or transcripts are available to assess management commentary or strategic direction. The company's financial disclosures are limited to standard reporting, with no additional insights into operational performance or future plans.

30-day price · 300927-4.43 (-14.5%)
Low$25.50High$33.55Close$26.06As of21 May, 00:00 UTC
Profile
CompanyNantong JiangTian Chemical Co Ltd
Ticker300927.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Nantong JiangTian Chemical Co Ltd is a Chinese specialty chemicals company that produces and sells chemical products for industrial applications.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with 92% confidence.

Nantong JiangTian Chemical Co Ltd has a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.72, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -108.6 million CNY, driven by capital expenditures of -166.3 million CNY, which may signal ongoing investment in operations. Profitability metrics show a return on equity of 2.01% and a return on assets of 0.93%, both below the typical thresholds for healthy performance in the specialty chemicals industry. The company's operating income of 22.6 million CNY and net income of 19.5 million CNY suggest limited profitability relative to its asset base. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes. The company's total revenue of 1.55 billion CNY is derived from a single disclosed segment, with no further breakdown provided. Growth trajectory is constrained by the company's current financial position. The company's free cash flow is negative, and capital expenditures are high, which may limit reinvestment in growth opportunities. There is no disclosed revenue growth in the most recent period, and no forward-looking guidance is available to assess future performance. The company faces moderate liquidity risk due to its negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no recent or disclosed share issuance activity. The company's capital structure remains stable, with no signs of imminent equity dilution. No recent filings or transcripts are available to assess management commentary or strategic direction. The company's financial disclosures are limited to standard reporting, with no additional insights into operational performance or future plans.
Key takeaways
  • The company has a moderate debt load and limited liquidity buffer.
  • Profitability is weak, with ROE and ROA below industry norms.
  • Revenue is concentrated in a single segment with no geographic diversification.
  • Growth is constrained by negative free cash flow and high capital expenditures.
  • Dilution risk is low, but liquidity risk remains a concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.55B
Gross profit$100.4M
Operating income$22.6M
Net income$19.5M
R&D
SG&A
D&A
SBC
Operating cash flow$160.1M
CapEx-$166.3M
Free cash flow-$108.6M
Total assets$2.10B
Total liabilities$1.13B
Total equity$969.4M
Cash & equivalents
Long-term debt$612.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$969.4M
Net cash-$612.3M
Current ratio1.7
Debt/Equity0.6
ROA0.9%
ROE2.0%
Cash conversion8.2%
CapEx/Revenue-10.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric300927Activity
Op margin1.5%0.4% medp25 -8.0% · p75 16.0%above median
Net margin1.3%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin6.5%20.8% medp25 14.9% · p75 24.0%bottom quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-10.7%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity63.0%59.0% medp25 54.9% · p75 72.9%above median
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 05:44 UTCJob: d48413d1